Mediar commences dosing in Phase II trial of MTX-463 for IPF
Change from baseline in forced vital capacity at 24 weeks is the trial’s primary endpoint.
Therapy Area
Iambic concludes dose escalation in Phase I/Ib trial of IAM1363
Moleculin announces efficacy results from trial of Annamycin for STS lung mets
Ascletis’s daily acne tablet set for China review after Phase III win
TRex Bio doses first healthy volunteer in trial of atopic dermatitis treatment
ASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancer
Byondis begins dosing subjects in Phase I trial of BYON4228 for solid tumours
Implementing pragmatic approaches for the patients and sites in oncology trials
